ClinicalTrials.gg
WithdrawnNCT06711640Updated Aug 1, 2025

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

A Phase 1 interventional study of LUCEMYRA (lofexidine) tablets in Opioid Withdrawal (Disorder) and Opioid Use Disorder, sponsored by USWM, LLC (dba US WorldMeds). Withdrawn at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study withdrawn prior to enrollment due to strategic portfolio decisions following divestiture of the investigational product.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing lofexidine in Opioid-Related Disorders — none open to participants now, 1 under way, none of them phase 3. lofexidine · Opioid-Related Disorders.

Enrollment
12th of 15
0 · median 30
Started
2025
the only one that year
Phase 1
7 of 15
none open now
Registered
15th of 15
by date
Lead sponsor
5 of 15
USWM, LLC (dba US WorldMeds)

Among the 15 studies testing lofexidine in Opioid-Related Disorders, this one is the 12th largest by enrollment, is the only one that started in 2025, is one of 7 in phase 1, and was the 15th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

None of the 15 studies testing lofexidine in Opioid-Related Disorders is open now. The open studies under Opioid-Related Disorders, anywhere →

Where they have run

About lofexidine

lofexidine: first FDA approval 2018 (LUCEMYRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing lofexidine in Opioid-Related Disorders as a file.
02

Study summary

The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to \<18 years old abruptly discontinuing opioid use.

Read the detailed description

This is a Phase 1, Open-label, PK, safety, and tolerability study of LUCEMYRA in adolescents aged ≥12 to \<18 years abruptly discontinuing opioid use. The objectives of the study are to evaluate the PK parameters, as well as safety and tolerability. The effectiveness of LUCEMYRA on the signs and symptoms of acute opioid withdrawal will also be evaluated.

03

Conditions studied

  • Opioid Withdrawal (Disorder)
  • Opioid Use Disorder

Keywords

  • Opioid Withdrawal Syndrome
  • LUCEMYRA
  • Lofexidine Hydrochloride
  • Opioid Withdrawal Management
  • Adolescent
  • opioid discontinuation
  • opioid
  • medications for opioid use disorder
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written minor assent obtained either in English or Spanish, as applicable, in accordance with local laws and Institutional Review Board (IRB) requirements. Additionally, written obtained from the participant's parent or LAR/guardian(s) in accordance with local laws and IRB requirements.
  2. Participant is willing and able to comply with scheduled visits, study dosing, laboratory tests, and other study procedures.
  3. Participant can swallow tablets the same size as LUCEMYRA.
  4. Adolescent male or female participants ≥12 years and \<18 years of age (at the time of study entry).
  5. Minimum weight ≥30 kg.
  6. Female participants of must agree to practice a medically acceptable method of (e.g., intrauterine device, hormonal contraception started at least one full cycle before study enrollment or barrier method in conjunction with spermicide) for the duration of the study (including 2 months after study completion). With approval by the Investigator, participants' parents or legal guardians may select abstinence as a form of birth control if deemed more appropriate. For the purposes of this study, all females are considered of childbearing potential unless they are confirmed by the Investigator to be premenarchal, biologically sterile, or surgically sterile (e.g., hysterectomy, bilateral oophorectomy, tubal ligation).
  7. All female participants, regardless of childbearing potential, must have a negative urine human chorionic gonadotropin (hCG) pregnancy test at Screening and prior to dosing on Day 1.
  8. History of opiate use as confirmed by diagnosis of OUD according to the , Fifth Edition (DSM-V); documentation of opioid use in the participant's medical record; or self-report of opioid use by participant and seeking treatment for OUD.
  9. Reported use of fentanyl, heroin, morphine, or any opioid with a half-life similar to heroin or morphine such as Vicodin®, Lortab®, Lorcet®, Percocet®, Percodan®, Tylox®, or hydrocodone (by any route of administration), or oxycodone (oxycodone and oxycodone time-released formulation when crushed and snorted, injected, or swallowed after chewing) for at least 21 of the past 30 days and use within 2 days of admittance to the inpatient clinic.
  10. Urine toxicology screen positive for opioids.
  11. Vital signs measured in a seated position after the participant has rested for 5 minutes must be as follows:

    1. Heart rate: ≥60 beats per minute
    2. Systolic blood pressure: ≥100 mmHg
    3. Diastolic blood pressure: ≥65 mmHg

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected pregnancy, planned pregnancy, or lactation.
  2. Treatment with an drug, device, or biological agent within 30 days prior to Screening, or during LUCEMYRA administration in this study.
  3. Any medical illness, condition, or clinical finding that, in the opinion of the Investigator and/or the Sponsor, would put the participant at undue risk or interfere with the participant's ability to complete the study.
  4. Any anticipated or scheduled surgery during the study period.
  5. Major surgery within 30 days before Screening.
  6. Have abnormal laboratory values as determined by the Investigator.
  7. Abnormal cardiovascular exam at Screening, including any of the following:

    1. Clinically significant abnormal (e.g., second or third-degree heart block, uncontrolled arrhythmia)
    2. with Fridericia's correction (QTcF) of ≥450 msec
    3. History of QT interval prolongation Note: if the QTcF interval meets the above criteria, the value may be confirmed by repeating the measurement (twice, if necessary). If 2 of 3 values meet the above criteria, the participant will be excluded from participation.
  8. Mild, moderate, or severe renal dysfunction, defined as an estimated \<90 mL/min/1.73 m2 at Screening.
  9. Hepatic dysfunction as defined by either of the following:

    1. or alanine aminotransferase >2 × (ULN) at Screening; or
    2. score of ≥7.
  10. cancer diagnosed within the previous year or diagnosis of any or neoplasm within 3 months prior to Screening, exclusive of basal cell carcinoma.
  11. History of lack of tolerance or lack of response to LUCEMYRA.
  12. Urine toxicology screen positive for methadone.
  13. Self-reported use of methadone in the 14 days prior to Screening.
  14. Current dependence, according to the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI KID) on any psychoactive substance (other than caffeine, nicotine, or the opioids listed in inclusion criterion #9) that requires detoxification or dose reduction as part of the pre-defined individual participant opioid withdrawal treatment goal.
  15. A psychiatric disorder that, in the opinion of the Investigator, requires ongoing treatment making study participation unsafe or treatment compliance difficult.
  16. History of suicidal behavior within the past 30 days or the participant is at risk of selfharm or harm to others as evidenced by endorsement of items 4 or 5 on the C-SSRS assessed prior to dosing on Day 1.
  17. Received any of the following drugs listed, within 14 days or 5 half-lives (whichever islonger) before Day -1: Amiodarone, armodafinil, buproprion, Celecoxib, Cimetidine, Cinacalet, Ciproflaxin, Diphenhydramine, Duloxetine, Enoxacin, Escitalopram, Fluoxetine, Fluvoxamine, Gefitinib, Hydroxychloroquine, Methoxsalen, Mexiletine, Moclobemide, Paroxetine, Propafenone, Quinidine, Ranitidine, Ritonavir, Sertraline, Terbinafine, Thiabendazole, Ticlopidine, Voriconazole
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LUCEMYRA: 0.54 mg

    The initial LUCEMYRA dose for this study will be based on weight. Participants who weigh ≥45 kg will receive three 0.18 mg tablets (0.54 mg) QID.

    Drug: LUCEMYRA (lofexidine) tablets

  • Experimental
    LUCEMYRA: 0.36 mg

    The initial LUCEMYRA dose for this study will be based on weight. Participants who weigh ≥30 to \<45 kg will receive two 0.18 mg tablets (0.36 mg) QID.

    Drug: LUCEMYRA (lofexidine) tablets

Interventions

  • Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.

06

What researchers measure

Primary outcomes

  1. Peak and trough plasma concentrations following daily LUCEMYRA doses during clinic confinement

    Time frame: Day 1 (2, 3, 4, 5, 9 hours post dose), Days 2-4 (pre-dose and 4 hours post first daily dose), Taper Days 1-4 (pre-dose and 4 hours post first daily dose), Day of Discharge

Secondary outcomes

  1. Estimation of apparent clearance and apparent volume of distribution for lofexidine and evaluation of possible covariates affecting PK

    Time frame: Day 1 post dose, Lucemyra fixed dosing days (4-8 days), Lucemyra Tapering days (4 days), discharge (1 day)

  2. Treatment-emergent adverse events (TEAEs)

    Time frame: Day 1 post dose, Lucemyra fixed dosing days (4-8 days), Lucemyra Tapering days (4 days), safety monitoring (2.5 days), discharge (1 day), 30 day follow up

  3. Vital signs: Heart Rate

    Time frame: Day -7 to -1, Dosing days (1 day up to 12 days), post last Lucemyra dose (Days 9 up to 14)

  4. Vital Signs: Systolic blood pressure

    Time frame: Day -7 to -1, Dosing days (1 day up to 12 days), post last Lucemyra dose (Days 9 up to 14)

  5. Vital Signs: Diastolic blood pressure

    Time frame: Day -7 to -1, Dosing days (1 day up to 12 days), post last Lucemyra dose (Days 9 up to 14)

  6. Electrocardiograms (ECGs) QT Interval

    Time frame: Day -7 to -1, Day 3

  7. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Day -7 to -1, Day 1, 2.5 days after last dose (discharge)

  8. Number of participants with abnormal laboratory test results (hematology)

    Safety laboratory assessments including blood tests for hematology will be performed.

    Time frame: Day -7 to -1, 2.5 days after last dose (discharge)

  9. Number of participants with abnormal laboratory test results (clinical chemistry)

    Safety laboratory assessments including blood tests for clinical chemistry will be performed.

    Time frame: Day -7 to -1, 2.5 days after last dose (discharge)

07

Study locations

1 site
  • Mountain Manor Treatment Center
    Baltimore, Maryland 21229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jan 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 2, 2024
StartEst.
Jun 2025
Primary completionEst.
Jan 2026
CompletionEst.
Feb 2026
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06711640
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Jun 2025 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion